

16th Euro Global Summit and Expo on

VACCINES & VACCINATION

June 19-21, 2017 Paris, France



Conference Series - America

One Commerce Center-1201, Orange St. #600, Wilmington, Zip 19899, Delaware, USA
P: +1-702-508-5200, F: +1-650-618-1417

Conference Series - UK

Kemp House, 152 City Road, London EC1V 2NX, Toll Free: +1-800-216-6499

Sunset 2

conference**series.com** 08:30-09:00

Opening Ceremony

Keynote Forum

- 09:00-09:05 **Introduction**
- 09:05-09:45 **Title: DNA immunization to prime the high quality antigen-specific B cell responses – a powerful pathway to induce protective antibodies**
Shan Lu, University of Massachusetts Medical School, USA
- 09:45-10:25 **Title: Pan-Lassa fever vaccine for prevention and post-challenge applications**
Igor S Lukashevich, University of Louisville, USA

Group Photo

Networking & Refreshments Break 10:25-10:45 @ Foyer

- 10:45-11:25 **Title: Altered vaccine immune responses to different Toll-Like receptor activators**
Kei Amemiya, US Army Medical Research Institute of Infectious Diseases, USA

Sessions: Vaccine Research & Development | Cancer Vaccines | HIV Vaccines | Vaccine Adjuvants & Delivery Technologies

Session Chair: Peter Johannes Holst, University of Copenhagen, Denmark

Session Introduction

- 11:25-11:50 **Title: Addressing challenges and solution for using T cell based assays for immune monitoring**
Magdalena Tary-Lehmann, Cellular Technology Limited, USA
- 11:50-12:15 **Title: Plant virus nanoparticles: New applications for developing countries**
Kathleen Hefferon, Cornell University, USA
- 12:15-12:40 **Title: Stability modeling to predict vaccine shelf-life and evaluate impact of temperature excursions from the “cold chain”**
Didier Clenet, Sanofi-Pasteur, France

Lunch Break: 12:40-13:30 @ N Café

- 13:30-13:55 **Title: Multi-epitope fusion antigen (MEFA), novel technology for structural vaccinology**
Weiping Zhang, Kansas State University, USA
- 13:55-14:20 **Title: Singapore Immunology Network's clinical immunomonitoring platform for the assessment of immune responses in cohort studies and clinical trials**
Brian Abel, A*STAR, Singapore
- 14:20-14:45 **Title: Mucosal vaccination with accessory antigens provides surprisingly robust protection against early SIV replication: Underappreciated role of location and immunodominance in vaccination against chronic infection**
Peter Johannes Holst, University of Copenhagen, Denmark

Sessions: Childhood Vaccines | Vaccines against Vector-borne Diseases

Session Chair: Brian Abel, A*STAR, Singapore

Session Introduction

- 14:45-15:10 **Title: Vaccination coverage cluster surveys in Middle Dreib–Akkar, Lebanon: Comparison of vaccination coverage in children aged 12-59 months pre- and post-vaccination campaign**
Randa Hamadeh, Ministry of Public Health, Lebanon
- 15:10-15:35 **Title: Responding to the threat of emergent infectious diseases**
Klaus Schwaborn, Valneva SE, France

Network & Refreshment Break: 15:35-15:55 @ Foyer

15:55-16:20 **Title: Polio outbreak stopped in the Middle East, efforts are still needed**
Randa Hamadeh, Ministry of Public Health, Lebanon

Young Researchers Forum

16:20-16:40 **Title: Modified MHCII associated invariant chain induces increased antibody responses against *Plasmodium falciparum* antigens after adenoviral vaccination**
Cyrielle Fougeroux, Copenhagen University, Denmark

16:40-17:00 **Title: Oil-based adjuvants and intradermal vaccine delivery: Th1 vs. Th2 response**
Zrinka Oreskovic, Veterinary Research Institute, Czech Republic

17:00-17:20 **Title: Bovine herpesvirus type 4-BAC as an attractive viral vector for vaccination and gene therapy**
Touraj Aligholipour Farzani, Ankara University, Turkey

Panel Discussion**Day 2 | June 20, 2017 | Tuesday****Sunset 2****Keynote Forum**

09:30-10:10 **Title: Live, attenuated vaccines in animal health: VitamFero's products and a few others**
Pascal Breton, VitamFero, France

10:10-10:50 **Title: Pneumococcal polysaccharide vaccines for elderly: Here, there and everywhere**
Ger T Rijkers, University College Roosevelt, Netherlands

Network & Refreshment Break 10:50-11:10 @ Foyer

Sessions: Immunization for Older Adults | Cancer Vaccines | Vaccines against Vector-borne Diseases | Human Preventive & Therapeutic Vaccines

Session Chair: Ger T Rijkers, University College Roosevelt, Netherlands

Session Introduction

11:10-11:35 **Title: Exploiting defects of type I interferon response in tumor cells for oncolytic immunotherapy with attenuated measles virus**
Jean-François Fonteneau, University of Nantes, France

11:35-12:00 **Title: Sequential administration of a MVA-based MUC1 cancer vaccine and the TLR9 ligand Litenimod (Li28) improves local immune defense against tumors**
Karola Rittner, Transgene SA, France

12:00-12:25 **Title: Biogenic selenium nanoparticles can shift the immune response of breast cancer bearing mice toward Th1 pattern**
Mohammad Hossein Yazdi, Tehran University of Medical Sciences, Iran

12:25-12:50 **Title: Recombinant lapidated subunit vaccines induce robust immunity against all four serotypes of dengue virus**
Hsin-Wei Chen, National Health Research Institutes, Taiwan

Lunch Break: 12:50-13:40 @ N Café

13:40-14:05 **Title: Therapeutic vaccination in chronic infectious diseases: The place of vectored vaccines**
Geneviève Inchauspé, Transgene SA, France

Sessions: Veterinary vaccines | Vaccine Research & Development | Vaccine Adjuvants & Delivery Technologies | HIV Vaccines

Session Chair: Pascal Breton, VitamFero, France

Session Introduction

14:05-14:30 **Title: A toll-like receptor 2 agonist-fused antigen enhanced antitumor immunity by increasing antigen presentation and the CD8 memory T cells population**
Chih-Hsiang Leng, National Health Research Institutes, Taiwan

14:30-14:55 **Title: Development of innovative vaccines by the combination of novel technologies**
Fumihiko Takeshita, Daiichi Sankyo Co. Ltd., Japan

14:55-15:20 **Title: Degradable emulsion as vaccine adjuvant reshapes antigen-specific immunity and ameliorates vaccine efficacy**

Ming-Hsi Huang, National Health Research Institutes, Taiwan

15:20-15:45 **Title: Kinetics of myeloid derived suppressor cells (MDSC) and their effect on vaccine-specific responses during the first year of life**

Ana Gervassi, Center for Infectious Disease Research, USA

Network & Refreshment Break: 15:45-16:05 @ Foyer

Panel Discussion

Poster Presentations: 16:05-16:30 @ Meeting Hall

EVACC 01

Title: Development of a peptide vaccine platform for brain tumor immunotherapy that incorporates adjuvant CD27 stimulation for enhanced T cell immunity

Katherine Riccione, Duke University, USA

EVACC 02

Title: Clostridium difficile flagellin FliC as an adjuvant to induce a protective gut mucosal immune response

Jean-François Bruxelles, University of Paris-Su, France

EVACC 03

Title: LPS/Endotoxins molecular diversity impacting vaccines and adjuvants activities and toxicity

Alexey Novokiv, LPS-Biosciences, France

EVACC 04

Title: Construction for minimal positive conditions for the safety of brain from vaccines to be supplied quickly at widespread epidemics

Sun Shin Yi, Soonchunhyang University, Republic of Korea

EVACC 05

Title: Development and preclinical evaluation of 15 pneumococcal polysaccharide CRM197 conjugate candidate vaccines in mouse model

Huyen T Pham, Konkuk University, South Korea

EVACC 06

Title: Study for establishment of 1st National Reference Standard for cell-derived Japanese encephalitis vaccine (Beijing strain)

Ji Young Hong, National Institute of Food and Drug Safety Evaluation, South Korea

EVACC 07

Title: Flavivirus nonstructural protein 1-based recombinant vaccines

Ching-Len Liao, National Health Research Institutes, Taiwan

EVACC 08

Title: Heterologous prime-boost tetravalent dengue vaccine strategy elicits complete protection against DENV-2 in non-human primates

Chutitorn Ketloy, Chulalongkorn University, Thailand

Awards for Poster Presentations

Day 3 | June 21, 2017 | Wednesday

Extended Networking & Lunch 12:30-13:20 @ N Café

Bookmark your dates

30th Euro Global Summit and Expo on

Vaccines & Vaccination

Jun 21-23, 2018 Barcelona, Spain

E: eurovaccines@conferenceseries.net; eurovaccines@vaccineconference.com

W: vaccines.global-summit.com/europe